Pfizer escapes proposed class action lawsuit over patient copay assistance

Two months after taking a loss in a U.S. Supreme Court appeal, which prevents Pfizer from implementing a cost-sharing assistance program for its heart disease drugs Vyndaqel and Vyndamax, the company has gotten a win in a parallel case in a different court in Washington, D.C.